Journal of Clinical Oncology & Advanced Therapy

Abstract

Background: The Women's Health Initiative (WHI) generated lasting restrictions on menopausal hormone therapy (MHT), largely through a framework in which breast cancer incidence functioned as a surrogate for clinical harm. This framework has been applied broadly across hormone formulations and has shaped two decades of clinical policy despite significant evidentiary limitations.

Evidence Review: This article provides a narrative review and conceptual analysis that integrates evidence from randomized controlled trials, large observational cohorts, chemoprevention research, meta-analyses, and bone-marrow niche studies. It focuses on how these data inform: (1) the relationship between breast cancer incidence and mortality in MHT and chemoprevention; (2) 20-year WHI breast cancer mortality outcomes; (3) formulation-specific distinctions between synthetic progestins and micronized progesterone; (4) the timing hypothesis as investigated in KEEPS and ELITE; (5) late-initiation effects reported in the Baik Medicare analysis; (6) systemic harms of estrogen deficiency, including bone marrow disruption; and (7) recognition of menopause as an endocrine insufficiency.

Findings: Breast cancer incidence has not been consistently validated as a reliable surrogate for breast cancer mortality in the MHT or chemoprevention literature, and in several large datasets reductions in incidence have not been accompanied by clear reductions in mortality. The adverse incidence signals from WHI are attributable primarily to the CEE plus MPA combination. To date, no study has yet demonstrated an increased breast cancer mortality signal specifically attributable to tE2+MP and current evidence repeatedly demonstrates a superior cardiovascular, metabolic, skeletal, and neurocognitive profile. The 2019 Collaborative Group meta-analysis, while large, cannot distinguish tE2+MP from other formulations because the number of micronized progesterone cases was too small to permit formulation-specific conclusion. Estrogen deficiency disrupts bone marrow niche function in ways that affect hematopoiesis, immune surveillance, and tumor dormancy regulation. Menopause appears to be the only common endocrine insufficiency in which physiologic hormone restoration is systematically time-limited and discouraged on the basis of age. This is a striking contrast to lifelong restoration norms in other endocrine conditions.

Conclusions: Current MHT policy reflects a sex-stratified therapeutic double standard. It is the only endocrine insufficiency affecting exclusively women, managed by normalizing deficiency rather than restoring physiology. Restriction of tE2+MP lacks formulation-specific evidentiary justification. The persistence of a restrictive MHT therapeutic framework, based on methodologically compromised and formulation-nonspecific evidence, exemplifies an asymmetric evidentiary standard that obstructs the full implementation of ecological women’s health.